Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancer.

Autor:	Silk AW; Merkel Cell Carcinoma Center of Excellence, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA ann_silk@dfci.harvard.edu isaac.brownell@nih.gov., Barker CA; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Bhatia S; Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, Washington, USA., Bollin KB; Hematology and Medical Oncology, Scripps MD Anderson Cancer Center, San Diego, California, USA., Chandra S; Hematology Oncology Division, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA., Eroglu Z; Department of Cutaneous Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, USA., Gastman BR; Melanoma and High-Risk Skin Cancer Program, Cleveland Clinic Cancer Center, Cleveland, Ohio, USA., Kendra KL; Division Of Medical Oncology, The Ohio State University, Columbus, Ohio, USA., Kluger H; Yale Cancer Center, Yale University, New Haven, Connecticut, USA., Lipson EJ; Bloomberg Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, Maryland, USA., Madden K; Melanoma/Cutaneous Oncology Program, New York University Langone Perlmutter Cancer Center, New York, New York, USA., Miller DM; Department of Medicine and Department of Dermatology, Massachusetts General Cancer Center, Boston, Massachusetts, USA., Nghiem P; Division of Dermatology, Department of Medicine, University of Washington, Seattle, Washington, USA., Pavlick AC; Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, New York, USA., Puzanov I; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA., Rabinowits G; Department of Hematology/Oncology, Miami Cancer Institute/Baptist Health South Florida, Miami, Florida, USA., Ruiz ES; Mohs and Dermatologic Surgery Center, Dana-Farber/Brigham and Women's Hospital, Boston, Massachusetts, USA., Sondak VK; Department of Cutaneous Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, USA., Tavss EA; Independent Contributor, New Brunswick, New Jersey, USA., Tetzlaff MT; Dermopathology Division, University of California San Francisco, San Francisco, California, USA., Brownell I; Dermatology Branch, National Institutes of Health, Bethesda, Maryland, USA ann_silk@dfci.harvard.edu isaac.brownell@nih.gov.
Jazyk:	angličtina
Zdroj:	Journal for immunotherapy of cancer [J Immunother Cancer] 2022 Jul; Vol. 10 (7).
DOI:	10.1136/jitc-2021-004434
Abstrakt:	Nonmelanoma skin cancers (NMSCs) are some of the most commonly diagnosed malignancies. In general, early-stage NMSCs have favorable outcomes; however, a small subset of patients develop resistant, advanced, or metastatic disease, or aggressive subtypes that are more challenging to treat successfully. Recently, immune checkpoint inhibitors (ICIs) have been approved by the US Food and Drug Administration (FDA) for the treatment of Merkel cell carcinoma (MCC), cutaneous squamous cell carcinoma (CSCC), and basal cell carcinoma (BCC). Although ICIs have demonstrated activity against NMSCs, the routine clinical use of these agents may be more challenging due to a number of factors including the lack of predictive biomarkers, the need to consider special patient populations, the management of toxicity, and the assessment of atypical responses. With the goal of improving patient care by providing expert guidance to the oncology community, the Society for Immunotherapy of Cancer (SITC) convened a multidisciplinary panel of experts to develop a clinical practice guideline (CPG). The expert panel drew on the published literature as well as their own clinical experience to develop recommendations for healthcare professionals on important aspects of immunotherapeutic treatment for NMSCs, including staging, biomarker testing, patient selection, therapy selection, post-treatment response evaluation and surveillance, and patient quality of life (QOL) considerations, among others. The evidence- and consensus-based recommendations in this CPG are intended to provide guidance to cancer care professionals treating patients with NMSCs. Competing Interests: Competing interests: CAB: consulting fees: Regeneron; contracted research: Alpha Tau Medical, Merck, Amgen, Elekta, and EMD Serono. SB: consulting fees: Genentech, Bristol Myers Squibb, EMD Serono, Sanofi Genzyme, and Exicure; contracted research: Bristol Myers Squibb, EMD Serono, Immune Design, Merck, Novartis, Oncosec, Nantkwest, Exicure, and Nektar. KBB: consulting fees: Iovance Biotherapeutics and Nektar Therapeutics. SC: consulting fees: Bristol Myers Squibb, Regeneron, Sanofi Genzyme, Novartis, EMD Serono, Exicure, and Pfizer; contracted research: Bristol Myers Squibb, Merck, Regeneron, Sanofi Genzyme, Novartis, EMD Serono, Exicure, and Pfizer. ZE: consulting fees: Regeneron, Genentech, Novartis, Natera, Pfizer, and OncoSec (advisory boards); research funding (to institution): Pfizer and Novartis. BRG: consulting fees: Quest Imaging (consultant/advisor) and Castle Biosciences (speaker); contracted research: NIT and Alkermes (research grant). KLK: contracted research: Merck, Bristol Myers Squibb, Karyopharm, Novartis, GlaxoSmithKline, Immunocore, and Iovance. HK: consulting fees: Nektar, Roche-Genentech, Pfizer, Iovance, Immunocore, Celldex, Array Biopharma, Merck, Elevate Bio, Instil Bio, and Bristol Myers Squibb; contracted research: Merck, Bristol Myers Squibb, and Apexigen (institutional research grants (to institution)). EJL: consulting fees: Array BioPharma, Bristol Myers Squibb, Eisai, EMD Serono, Genentech, MacroGenics, Novartis, Merck, Odonate Therapeutics, OncoSec, Regeneron, and Sanofi Genzyme; contracted research: Bristol Myers Squibb, Merck, and Regeneron. KM: consulting fees: Pfizer (advisory board). DMM: consulting fees: Sanofi, Regeneron, Intellisphere LLC, OncLive, and Checkpoint Therapeutics; ownership interest: Checkpoint Therapeutics. PN: consulting fees: EMD Serono, Pfizer, 4SC, Wolters Kluwer Health, Merck, Sanofi Genzyme, and Regeneron; contracted research: EMD Serono and Bristol Myers Squibb; other: secretary–treasurer for Society of Investigative Dermatology; partner consulting fees: Pfizer and Kadmon; partner contracted research: Millenium Pharmaceuticals, Amgen, Novartis, Kadmon, Pfizer, Syndax Pharmaceuticals, and Incyte; partner other: President of American Society of Hematology. ACP: consulting fees: Regeneron, Bristol Myers Squibb, and Merck; fees for non-CE services: Bristol Myers Squibb; contracted research: Merck, Bristol Myers Squibb, Iovance, Regeneron, Takeda, Ideaya, and Replimune (all payments to institution). IP: consulting fees: Merck, Amgen, Nouscom, Nektar, and Iovance; other: Bristol Myers Squibb (medical writing/article processing charges); ownership interest: Celldex. GR: consulting fees: Sanofi Genzyme, Regeneron, EMD Serono, Pfizer, Castle, and Merck; ownership interest: Regeneron and Syros Pharmaceuticals. ESR: consulting fees: Sanofi, Leo Pharma, Checkpoint Therapeutics, Pellepharm, and Jounce. AWS: consulting fees: Bristol Myers Squibb, Merck, and EMD Serono. VKS: consulting fees: Merck, Regeneron, and Eisai; other: Bristol Myers Squibb and Polynoma (data safety monitoring boards). MTT: consulting fees: Nanostring LLC, Bristol Myers Squibb, Merck, Myriad Genetics, and Seattle Genetics. EAT: nothing to disclose. IB: Nothing to disclose. Society for Immunotherapy of Cancer (SITC) staff: SMW - shares owned: Pacific Biosciences of California Inc and Editas Medicine Inc; ME, CG, EG, and AK - nothing to disclose. (© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu